Report includes chapters which deeply display the following deliverable about industry :
• Fibromyalgia Treatment Market Research Objective and Assumption
• Fibromyalgia Treatment Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Fibromyalgia Treatment Market Dynamics, Regulations, and Trends Analysis - Market
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system
Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Fibromyalgia Treatment Market, By Regions
• Fibromyalgia Treatment Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Fibromyalgia Treatment Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Fibromyalgia Treatment Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Fibromyalgia Treatment Market Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Market Dynamics
Key players in the market are focusing on frequent research and development activities for
development of novel medications for fibromyalgia treatment. Launch of novel drugs in the
market for fibromyalgia is expected to boost the fibromyalgia treatment market growth over the
forecast period. For instance, drug candidate IMC-1 is being developed by Innovative Med
Concepts, which received fast track designation from the U.S. FDA in 2016
In December 2018, Aptinyx Inc. announced positive results from an interim analysis of an
exploratory study of its novel NMDA receptor (NMDAr) modulator, NYX-2925, in subjects with
fibromyalgia. Subjects in the study received daily oral doses of NYX-2925 at two dose levels, 20
mg and 200 mg, as well as placebo, over the course of six weeks.